DETECTION OF COLORECTAL NEOPLASMS
The present disclosure provides, among other things, methods for colorectal neoplasm detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for adenoma and/or early stage colorectal cancer detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for detection (e.g., screening) that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for screening that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR and/or using massively parallel sequencing (e.g., next-generation sequencing).
1 .- 10 . (canceled)
11 . A method of detecting a methylation status in a human subject suspected of having a colorectal neoplasm, the method comprising:
determining a methylation status for a methylation locus within gene BARHL1 in a sample of deoxyribonucleic acid (DNA) from a human subject suspected of having the colorectal neoplasm
and
detecting the colorectal neoplasm in the human subject based at least on said determined methylation status.
12 . The method of claim 11 , wherein detecting the colorectal neoplasm comprises a member selected from the group consisting of (i) classifying the subject as having advanced adenoma, (ii) classifying the subject as having polyposis, (iii) classifying the subject as having colorectal cancer, (iv) classifying the subject as having at least one of the conditions advanced adenoma, polyposis, and colorectal cancer, either with or without identifying which of those conditions the subject has, and (v) classifying the subject as having at least one of the conditions advanced adenoma and colorectal cancer, either with or without identifying which of those conditions the subject has.
13 .- 14 . (canceled)
15 . The method of claim 11 , wherein the methylation locus within gene BARHL1 comprises at least a portion of BARHL1 '614 [chr9:132579614-132579683] (SEQ ID NO: 41).
16 . (canceled)
17 . The method of claim 11 , wherein the DNA is isolated from blood or plasma of the human subject.
18 . The method of claim 11 , wherein the step of determining the methylation status further comprises determining a relative amount of methylated and unmethylated CpGs and/or determining a read-based pathological methylation pattern.
19 . The method of claim 11 , wherein methylation status is determined using methylation sensitive restriction enzyme quantitative polymerase chain reaction (MSRE-qPCR).
20 .- 21 . (canceled)
22 . The method of claim 11 , wherein the methylation locus of BARHL1 is or comprises at least one CpG dinucleotide.
23 .- 44 . (canceled)
45 . The method of claim 11 , wherein the DNA is cell-free DNA of the human subject.
46 . The method of claim 11 , wherein methylation status is determined using massively parallel sequencing.
47 . The method of claim 11 , wherein each methylation locus is equal to or less than 5000 bp in length.
48 . The method of claim 11 , comprising determining the methylation status of each of the one or more markers using next generation sequencing (NGS).
49 . The method of claim 11 , comprising determining whether the methylation locus within gene BARHL1 is hypermethylated and detecting the colorectal neoplasm based on, at least, hypermethylation of BARHL1.